Maze Therapeutics, Inc.
MAZEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Maze Therapeutics, Inc. (MAZE) is listed under Biotechnology. The company carries a $1.46B market cap, placing it firmly in the small-cap category. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Market Cap
$1.46B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.30
EPS (TTM)
$-2.44
EPS (Fwd)
$-3.18
ROE
-37.4%
ROA
-21.8%
Cash
$411.1M
Total Debt
$60.4M
Free CF
-$63.6M
52W Change
63.6%
Annual Financials
Cash vs Debt
Where MAZE stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, MAZE finished 18.37% below its 150-day moving average ($32.50) and 22.68% below its 200-day moving average ($34.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MAZE overbought or oversold?
At the September 2, 2026 close, MAZE's RSI(14) was 44.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Maze Therapeutics, Inc. holds $411.1M in cash against $60.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$63.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MAZE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.